Category: New Diagnostics

ALCMI and Biocept Announce a Landmark Liquid Biopsy Clinical Trial

The Addario Lung Cancer Medical Institute (ALCMI) and Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announce a clinical collaboration and initiation of the landmark ALCMI-009 liquid biopsy clinical trial, which was developed and will be conducted by ALCMI and its consortium of… Read More

Posted by ALCF Staff on May 10th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

Lung Cancer in Women: Lets do something about it!

Bonnie J. Addario Lung Cancer Foundation partners with the American Lung Association to fund $250,000 on innovative and transformational research to defeat lung cancer in women An unfortunate and often unknown fact is that lung cancer is the leading cancer killer in women, estimated to be the cause of 1 in 4 female cancer deaths… Read More

Posted by Dr. Guneet Walia on February 25th, 2016

Today is World Cancer Day. Here’s how YOU can #BeTheSolution!

Bonnie J. Addario Lung Cancer Foundation Launches $180,000 Crowdsourcing Challenge to Increase Clinical Trial Patient Enrollment. Each year, in honor of World Cancer Day, the Bonnie J. Addario Lung Cancer Foundation (ALCF) launches a unique, international crowdsourcing challenge that leverages the power of the crowd, encouraging innovators from both within and more importantly, outside healthcare… Read More

Posted by Dr. Guneet Walia on February 4th, 2016

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients

The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments. ALCF works everyday to educate patients and their families on the latest advancements, encourage participation in clinical trials and fund life-saving research on… Read More

Posted by Dr. Guneet Walia on December 18th, 2015

New treatment approved for drug-resistant lung cancer

Tagrisso approved for EGFR T790M mutation positive NSCLC patients In another win for lung cancer patients, the Food and Drug Administration today granted accelerated approval to Tagrisso (Osimertinib or AZD9291 manufactured by AstraZeneca) this morning for patients whose disease has progressed on EGFR-targeted therapies, and whose tumors express a specific mutation in EGFR- the T790M… Read More

Posted by Dr. Guneet Walia on November 13th, 2015

FDA Approves Keytruda/ Pembrolizumab for Non-Small Cell Lung Cancer

The US Food and Drug Administration (FDA) today granted accelerated approval to an immunotherapy drug, Keytruda or Pembrolizumab, for patients with advanced, metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments (chemotherapy or targeted therapy) and whose tumors express the protein PDL1. Based on the FDA approval, patients with EGFR or… Read More

Posted by Dr. Guneet Walia on October 2nd, 2015

Immunotherapy for Lung Cancer: Why should you be excited?

Lung cancer is one of the few cancers that has shown remarkable responses to immunotherapy, one reason being its high mutation burden, i.e. these tumors are a very high number of mutations (partly due to exposure to the carcinogens in tobacco/smoke). Recent studies have shown that a tumors with higher mutational loads are more likely… Read More

Posted by Dr. Guneet Walia on August 4th, 2015